Capricor Completes Submission of Biologics License Application for Treatment of Duchenne

 -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy-

-BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku-

https://www.globenewswire.com/news-release/2025/01/02/3003570/0/en/Capricor-Therapeutics-Completes-Submission-of-Biologics-License-Application-to-the-U-S-FDA-for-Deramiocel-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html